Two important drug classes used in CKD associated with T2D are sodium-glucose cotransporter-2 inhibitors (SGLT2is) and the nonsteroidal mineralocorticoid receptor antagonist (ns-MRA) finerenone. This evidence concerns the gene NR3C2 and type 2 diabetes mellitus.